《新股表現》朝聚眼科(02219.HK)暗盤高開逾13%報12元
根據輝立交易平台顯示,明天掛牌的朝聚眼科(02219.HK)暗盤高開13.2%報12元欠承接,掉頭曾低見10元,現造10.7元,較上市價10.6元,高0.9%,成交13萬股。
朝聚眼科是內地華北地區領先、全國知名的眼科醫療服務集團。根據弗若斯特沙利文報告,於民營眼科醫院中,按2020年收益總額計,朝聚於內蒙古排名第一、在華北地區排名第二及在中國排名第五。是次來港上市共發售約1.71億股(包括3,343萬股舊股),並已引入包括富國基金、Gigantic Wealth、The Valliance Fund及通柏資本(香港)4名基石投資者,合共認購7,467.45萬股;其中10%公開發售獲近113倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率僅5.67%;股份以招股範圍(9.48-10.6元)上限定價,料集資淨額約13.57億元,主要用作設立新醫院、收購醫院及升級信息技術系統等。上市聯席保薦人分別為海通國際及華泰金融香港。
朝聚眼科醫療於1988年在內蒙古包頭成立。集團2018-2020年收入分別為6.33億元人民幣(下同)、7.15億元及7.94億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.